AU3737500A - Method of preventing the death of retinal neurons and treating ocular diseases - Google Patents

Method of preventing the death of retinal neurons and treating ocular diseases

Info

Publication number
AU3737500A
AU3737500A AU37375/00A AU3737500A AU3737500A AU 3737500 A AU3737500 A AU 3737500A AU 37375/00 A AU37375/00 A AU 37375/00A AU 3737500 A AU3737500 A AU 3737500A AU 3737500 A AU3737500 A AU 3737500A
Authority
AU
Australia
Prior art keywords
death
preventing
ocular diseases
treating ocular
retinal neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37375/00A
Inventor
Napoleone Ferrara
Audrey Goddard
Austin L. Gurney
Caroline Hebert
William J. Henzel
Rhona C. Kabakoff
Robert D. Klein
Ivar J. Kljavin
Sophia S. Kuo
Monique La Fleur
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU3737500A publication Critical patent/AU3737500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
AU37375/00A 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases Abandoned AU3737500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12395799P 1999-03-12 1999-03-12
US60123957 1999-03-12
PCT/US2000/006319 WO2000053760A2 (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Publications (1)

Publication Number Publication Date
AU3737500A true AU3737500A (en) 2000-09-28

Family

ID=22411919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37375/00A Abandoned AU3737500A (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Country Status (2)

Country Link
AU (1) AU3737500A (en)
WO (1) WO2000053760A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2002079383A2 (en) * 2001-03-30 2002-10-10 Genentech, Inc. Fizz1 for metabolism regulation
EP1596926A2 (en) 2003-02-07 2005-11-23 The Johns Hopkins University Hypoxia induced mitogenic factor
RU2531523C3 (en) * 2008-06-25 2022-05-04 Новартис Аг STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
CN104768567B (en) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 Therapeutic alliance and composition for wound healing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0651650A4 (en) * 1992-07-08 1996-04-17 Celtrix Pharma METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b).
WO1995014772A1 (en) * 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO1999037671A1 (en) * 1998-01-27 1999-07-29 Eli Lilly And Company Vegf related gene and protein
DK1064382T3 (en) * 1998-03-17 2008-12-08 Genentech Inc Homologous polypeptides for VEGF and BMP1
CA2334075A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Bone morphogenic protein
AU771751C (en) * 1998-12-01 2006-04-06 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
DK1137773T3 (en) * 1998-12-07 2008-12-08 Zymogenetics Inc Liquid Factor Homolog ZVEGF3

Also Published As

Publication number Publication date
WO2000053760A2 (en) 2000-09-14
WO2000053760A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
AU4582797A (en) Methods for treatment of retinal diseases
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
HK1040185A1 (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
EP1592435A4 (en) Ophthalmic formulation for the prevention and treatment of ocular conditions
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
EP1455778A4 (en) Methods for the treatment of peripheral neural and vascular ailments
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
NL1010351A1 (en) Esters of carotenoids for use in the prevention and treatment of eye diseases.
AU1794801A (en) Method for treatment and prevention of physiological shock
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU3737500A (en) Method of preventing the death of retinal neurons and treating ocular diseases
AU1920501A (en) The use of caspase 9 inhibitors to treat ocular neural pathology
CA2282682A1 (en) Tazarotene and corticosteroid treatment for psoriasis
WO2001043731A3 (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
ZA971607B (en) Methods of treatment of allergic diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase